Best Peptides for Body Recomposition
Simultaneous fat loss and muscle preservation
These peptides rank highest for body recomposition based on research evidence, mechanism of action, and community results. Use our AI stacker to build a personalized protocol for your budget.
Build Your Body Recomposition StackTop Peptides for Body Recomposition
Semaglutide
Active ingredient in Ozempic/Wegovy. Mimics GLP-1 to signal fullness and slow gastric emptying. STEP trials showed 14.9% weight loss at 68 weeks.
Tirzepatide
Active ingredient in Mounjaro/Zepbound. Dual GLP-1/GIP agonist — more effective than semaglutide. SURMOUNT-1 showed up to 22.5% weight loss at 72 weeks.
Retatrutide
Next-gen triple agonist from Eli Lilly hitting GLP-1, GIP, and glucagon receptors. Phase 2 showed 24.2% weight loss at 48 weeks — highest of any incretin therapy. At low doses, optimizes metabolism without major weight loss.
CagriSema
Semaglutide + cagrilintide combo in Phase 3 trials. Strongest weight loss data of any injectable to date, surpassing semaglutide alone through dual appetite/satiety targeting.
Survodutide
Dual GLP-1/glucagon weight loss peptide from Boehringer Ingelheim. The glucagon component adds liver fat reduction, promising for fatty liver disease alongside obesity.
Mazdutide
Dual GLP-1/glucagon receptor drug from Innovent Biologics. Strong weight loss and metabolic results. Already approved in China for obesity.
Orforglipron
First oral non-peptide GLP-1 agonist in late-stage trials. A daily pill alternative to injectable GLP-1s with promising early weight loss data.
Tesamorelin
FDA-approved GH booster for reducing visceral belly fat in HIV-associated lipodystrophy. Trials showed ~15-18% visceral fat reduction. Overall weight loss is modest vs GLP-1 agonists.
MOTS-c
Mitochondrial DNA-encoded peptide that activates AMPK, improving insulin sensitivity, fat burning, and mimicking exercise at the cellular level. Stacks well with SS-31 and NAD+.
Best Synergy Combos
Mitochondrial-axis overlap. SS-31 binds cardiolipin to stabilize inner-membrane structure; NAD+ is the redox substrate for sirtuin and electron-transport flux. Together they target the same organelle through complementary nodes (structure + cofactor pool).
GHRH × GHRP convergence on the somatotroph. CJC-1295 (GHRH analog) primes the pituitary; ipamorelin (selective GHRP) triggers GH release without ACTH or prolactin elevation.
AMPK convergence at different tiers. Retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors (Phase 2 NEJM 2023, N=338); MOTS-c is a mitochondrial-derived peptide that upregulates AMPK and GLUT4 translocation in muscle. Hormone-axis × intracellular-energy-sensor pair.
GLP-1/GIP/glucagon triple-receptor signaling combined with NAD+ as substrate for sirtuin-driven lipid oxidation gene expression. Hormonal-axis × cofactor-pool pair.
Get a Personalized Body Recomposition Protocol
Set your budget and goals — our AI picks the optimal peptides with synergy scoring and dosing.
Build Your Stack — It's Free